61,671 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by Raymond James Financial Inc.

Raymond James Financial Inc. acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 61,671 shares of the company's stock, valued at approximately $3,845,000. Raymond James Financial Inc. owned approximately 0.18% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Arizona State Retirement System grew its position in shares of TransMedics Group by 1.9% during the 4th quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after acquiring an additional 184 shares during the period. National Bank of Canada FI increased its holdings in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after purchasing an additional 262 shares during the period. Quarry LP raised its holdings in shares of TransMedics Group by 557.1% in the 3rd quarter. Quarry LP now owns 368 shares of the company's stock valued at $58,000 after acquiring an additional 312 shares in the last quarter. Park Avenue Securities LLC raised its stake in TransMedics Group by 3.8% in the fourth quarter. Park Avenue Securities LLC now owns 8,797 shares of the company's stock valued at $548,000 after purchasing an additional 322 shares in the last quarter. Finally, Captrust Financial Advisors raised its position in shares of TransMedics Group by 20.6% during the 3rd quarter. Captrust Financial Advisors now owns 1,988 shares of the company's stock valued at $312,000 after buying an additional 340 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on TMDX shares. Oppenheimer restated an "outperform" rating and issued a $125.00 target price on shares of TransMedics Group in a research report on Tuesday, December 3rd. Canaccord Genuity Group reiterated a "buy" rating and set a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $75.00 price target (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Robert W. Baird decreased their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an "outperform" rating for the company in a report on Wednesday, December 11th. Finally, Piper Sandler cut their target price on shares of TransMedics Group from $110.00 to $90.00 and set an "overweight" rating on the stock in a research note on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.70.

TransMedics Group Stock Down 2.6 %

TMDX traded down $1.86 during midday trading on Friday, reaching $68.58. The company's stock had a trading volume of 612,338 shares, compared to its average volume of 1,322,479. TransMedics Group, Inc. has a 1 year low of $55.00 and a 1 year high of $177.37. The stock's 50-day moving average is $69.11 and its 200-day moving average is $87.69. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of 72.96 and a beta of 2.12. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.